SELDI-TOF-MS技术在肝癌诊断中的临床应用性研究  

Application of SELDI-TOF-MS technique in diagnosis of hepatocellular carcinoma

作　　者：刘池波[1] 梁勇[1] 潘春琴[1] 孙灵芬[1] 金茜[1] 

机构地区：[1]台州市立医院,浙江台州318000

出　　处：《中国热带医学》2007年第1期18-20,共3页China Tropical Medicine

摘　　要：目的应用表面增强激光解吸电离飞行时间质谱技术(SELDI-TOF-MS)筛选肝癌患者血清标志蛋白,探讨作为临床诊断指标的最佳标志蛋白组合模式。方法对40例肝癌、20例肝硬化和60例健康志愿者的血清进行分析,并反复分析寻找合理运算规则以确定能够区分肝癌和健康志愿者与肝硬化患者的蛋白组学图谱。结果肝癌、肝硬化患者与健康对照组血清蛋白质指纹图谱之间有5个标志蛋白在肝癌患者血清中高表达,1个标志蛋白在肝癌患者血清中低表达。其中2个蛋白质峰[8943 Da和4477 Da质荷比(m/z)]组合构建的诊断模型Ⅰ鉴别肝癌和健康志愿者,灵敏度为90％(36/40),特异性为100％(60/60)。3个蛋白质峰(4477Da、13761Da和4097Da m/z)组合的诊断模型Ⅱ鉴别肝癌组与肝硬化组的灵敏度为85％(34/40),特异性为90％(18/20)。结论SELDI-TOF-MS技术的特异性及敏感度远远高于目前所采用的某一单独的标志物的血清学诊断,其结果对进一步研究肝癌的蛋白质组学改变及其临床应用可能具有重要意义。Objective To screen serum biomarkers in patients with hepatrometry（SELDI - TOF- MS） technique. Methods Proteinic spectra were generated by SELDI - TOF- MS. The sera from 60 unaffected healthy donors、40 patients with liver cancer and 20 patients with hepatocirrhosis were analyzed for selection of the specific protein of liver cancer. The biomarker patterns were used. Resttlts Five protein markers were highly expressed and one protein markers was lowly expressed in serum of liver cancer patients. Two protein peaks （ 8943Da and 4477Da m/z） were used to set up diagnostic model I for differentiation of liver cancer patients and healthy volunteers with a sensitivity of 90% （36/40） and specificity of 10% （60/60）. The other three protein peaks （4477Da,13761Da and 4097Da m/z） were used to set up a diagnostic model Ⅱ for differentiation of liver hepatocelllular carcinoma patients and hepatocirrhosis diseases with a sensitivity and specificity of 85 % （34/40） and 90% （18/20）, respectively. Conclusion SELDI - TOF - MS offers a unique platform for the proteomic detection of hepatocelllular carcinoma and it is also a noninvasive method for further study of the proteomic changes in the development and progression of liver cancer.

关 键 词：表面增强激光解析电离飞行时间质谱 蛋白质芯片 肝癌 

分 类 号：R735.7[医药卫生—肿瘤]